Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

breast cancer

28th Oct 2025

ERICA study plain language summary: olanzapine for nausea in breast cancer patients on trastuzumab deruxtecan

28th Oct 2025

Plain language summary of POLARIS: real-world palbociclib effectiveness and life quality impact

28th Oct 2025

CheckMate 7FL trial: nivolumab versus placebo in estrogen-positive breast cancer treatment: plain language summary

17th Mar 2025

A plain language summary of the TROPiCS-02 study: impact of sacituzumab govitecan on quality of life in patients with HR-positive/HER2-negative breast cancer

16th Sep 2024

Plain language summary of the ASCENT Study: Sacituzumab Govitecan for metastatic triple-negative breast cancer

12th Aug 2024

Plain language summary of the monarchE study: Abemaciclib with endocrine therapy for HR+, HER2-, node-positive and high-risk early breast cancer

1st Sep 2021

A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy